Inventia Healthcare Limited IPO – Review, Allotment, Subscription, GMP & DRHPLast Updated Date: Aug 31, 2023
Inventia Healthcare Limited are a pharmaceutical development and manufacturing company headquartered in Mumbai with over 30 years of operations. Their focus is on development of value added oral solid dosage formulations (“OSDF”). Over the years, they have developed capabilities in offering end to end solutions in the product development process, right from research and development all the way to final manufacturing and packaging . Inventia Healthcare Limited IPO comprises of [●] Equity shares, face value of Rs.10 each.
Let’s have a detailed review of the company and analytics of the Inventia Healthcare Limited IPO release date, IPO offer price, subscription, Inventia Healthcare Limited IPO allotment, grey market price and other details like the company’s background, its financial positions, its promoters and other related things.
Inventia Healthcare Limited IPO Review & Ratings
|IPO Ratings & Review|
|Top Brokers Review||7.9/10|
Summary of Inventia Healthcare Limited IPO
Inventia Healthcare Limited are a pharmaceutical development and manufacturing company headquartered in Mumbai with over 30 years of operations. Their focus is on development of value added oral solid dosage formulations (“OSDF”). Over the years, they have developed capabilities in offering end to end solutions in the product development process, right from research and development all the way to final manufacturing and packaging.The Issue comprises of a Public Issue of [●] Equity shares of face value of Rs.10.00 each fully paid up.
From FY 2014-15 to FY 2016-2017, as per the Restated Financial Statements,
From fiscal 2016 to 2017, company’s revenue from operations and net profit has increased at a growth rate of 13.43% and 53.50%, respectively.
For the period ended March 31, 2018, FY 2016-17 and FY 2015-16, its revenue from operations was Rs. 3,108.21 Millions, Rs. 2,804.19 Millions and Rs. 2,472.28 Millions, respectively representing growth of 13.43% from the FY 2015-16 to FY 2016-17. For the period ended March 31, 2018, FY 2016-17 and FY 2015-16 our net profit was Rs. 261.24 Millions, Rs. 241.40 Millions and Rs. 164.54 Millions, respectively, representing a growth of 53.50 % from the FY 2015-16 to FY 2016-17.
- During the financial year 2017-18 the Other Income of our company decreased to Rs. 15.79 Millions as against Rs. 30.48 Millions for the financial year 2016-17 .
- Company’s Net Profit after tax for the year 2016-17 is Rs.157.08 Millions from the year 2015-16 of Rs. 141.84 Millions showing an increase of 11.34% from last year, showing remarkable performance.
The Promoter of this company is Janak Shah, Maya Shah, Ankur Shah Trust and Vishal Shah Trust. The lead manager to the issue is ICICI Securities Limited and Centrum Capital Limited and the Registrar to this issue is Link Intime India Private Limited .
Open Free* Demat A/C Now! Fill the details below
Inventia Healthcare Limited IPO Date
The opening and the closing date of Inventia Healthcare Limited IPO is not known yet.
Inventia Healthcare Limited IPO Subscription
|Day / Date||QIB||NII||RII||Total Subscription|
|Shares Offered or Net Issue|
The shares subscribed by the public will be updated herein on a daily basis, once the IPO is open for subscription.
Inventia Healthcare Limited IPO Allotment Status
Here, you can find the Allotment Status of this IPO.
Inventia Healthcare Limited IPO Price Band
The face value of each share is Rs 10, but the price band of the IPO is not yet disclosed.
Inventia Healthcare Limited IPO Equity Share Offering
[●] Equity Shares of Rs 10/- each but Issue Price is yet to be disclosed .
Inventia Healthcare Limited – Company Overview
Inventia Healthcare Limited are a pharmaceutical development and manufacturing company headquartered in Mumbai with over 30 years of operations. Their focus is on development of value added oral solid dosage formulations (“OSDF”). Over the years, they have developed capabilities in offering end to end solutions in the product development process, right from research and development all the way to final manufacturing and packaging .They develop and manufacture their products in-house. Once a product is developed, the Company partner with mid-sized and large pharmaceutical companies and distributors which have a local or multi-national presence to sell our products across various jurisdictions.
Unlike contract research and contract manufacturing companies, for most of their products, the proprietary technology and manufacturing rights remain with their Company and these products are sold on a non-exclusive basis under the partner’s brand name.
The Company is promoted by Janak Shah, Maya Shah, Ankur Shah Trust and Vishal Shah Trust and is the guiding force behind the growth and strategic decisions of the Company.
Competitive Strengths of Inventia Healthcare Limited :
- Accredited research and manufacturing facilities which enables us to provide end to end solutions as well as serve multiple jurisdictions
- Multifaceted product selection process targeting value added OSDF products which have high margins
- Flexible business model and long-standing relationship with partners
- Experienced management team with extensive industry experience and proven track record
Business strategies of Inventia Healthcare Limited :
- Continue to focus on value added OSDF with high entry barriers which can be marketed in multiple regions
- Foray into high growth injectables segment
- Foray into the nutraceuticals segment
- Expand research and development and manufacturing capabilities
- Selling finished formulations under their brand and bid for government and institutional tenders in the domestic market
Inventia Healthcare Limited – Financial Statements
A quick look into the past financial performance of the company to understand its performance of business and evaluate the growth prospectus:
|Amount (in INR & Millions)|
|Profit After Tax||157.08||141.84||133.53||44.05||28.48|
Earnings per Equity Share (in Millions)
|Basic & Diluted||15.04||13.58||12.79|
From the above statements, one could find that the Inventia Healthcare Limited may perform well.
Inventia Healthcare Limited IPO – Promoters
The Promoter of this company are:
- Janak Shah
- Maya Shah
- Ankur Shah Trust
- Vishal Shah Trust
List of Related Parties (Key Managerial Personnel)
- Janak Shah
- Maya Shah
- Ankur Shah
Interest in promotion of the Company
Company is currently promoted by the Promoters in order to carry on its present business. Promoters are interested in the Company to the extent of their shareholding and directorship of the Individual Promoter in the Company and the dividend declared, if any, by the Company. The Promoters are interested in the transactions entered into the Company and the Promoter Group.
The promoters along with the promoter group will continue to hold collectively some percentage of the equity share capital of the company. As a result of the same, they will be able to exercise significant influence over the control of the outcome of the matter that requires approval of the majority shareholders vote.
Interest in Intellectual Rights of the Company
Promoters has not shown any interest in acquiring the intellectual rights of the company.
Inventia Healthcare Limited IPO Offer Details or Issue Details
|Particulars||No. Of Equity Shares|
|Equity Shares Offered||Up to [●] Equity Shares, aggregating up to Rs.[●] million|
|Reserved for Market Makers||Up to [●] Equity Shares, aggregating up to Rs.1,250 million|
|Net Issue to the Public||Up to 3,164,000 Equity Shares, aggregating up to Rs.[●] million|
|Retail Investors Portion||Not less than [●] Equity Shares|
|Non-Retail Investors Portion||Not less than [●] Equity Shares|
|Equity Shares outstanding prior to the Issue||10,444,000 Equity Shares|
|Equity Shares outstanding after the Issue||[●] Equity Shares|
Inventia Healthcare Limited IPO Issue Object
These are the IPO Issue Objects of the company
- Pre-payment or repayment of all or a portion of certain outstanding borrowings availed by our Company;
- General corporate purposes.
Inventia Healthcare Limited IPO – Basis of the Offer Price
The issue price is determined by the company in consultation with the Lead manager on the basis of the following qualitative and quantitative factors.
Qualitative factors are:
- Accredited research and manufacturing facilities approved by various regulatory authorities;
- Multifaceted product selection process targeting high margin value added OSDF products;
- Flexible business model and long-standing relationship with partners;
- Experienced management team with extensive industry experience.
The relevant quantitative factors are:
|Basic & Diluted EPS||RONW (%)|
- Industry P/E Ratio:
- Competitive Peers:
|Particulars||Face Value (in Rs.)||EPS (In Rs.)||P/E Ratio||RONW (%)||NAV (In Rs.)|
|Caplin Point Laboratories Limited||2.00||19.16||27.39||39.75||48.21|
|Granules India Limited||1.00||547||21.81||10.71||51.38|
|Marksans Pharma Limited||1.00||0.80||47.88||7.45||11.74|
Inventia Healthcare Limited IPO Lead Managers
|ICICI Securities Limited
Centrum Capital Limited
Inventia Healthcare Limited IPO Registrar to offer
|Registrar to the Offer|
|LINK INTIME INDIA PRIVATE LIMITED
C-101, 1st Floor, 247 Park, L.B.S. Marg,
Vikhroli (West), Mumbai – 400 083, India
Tel: +91 22 49186200; Fax: +91 22 4918 6195
Investor Grievance Id: firstname.lastname@example.org
Contact Person: Shanti Gopalkrishnan
SEBI Registration Number: INR000004058
- Statutory Auditor – S R B C & CO LLP, Chartered Accountants.
- Peer Review Auditor – S R B C & CO LLP, Chartered Accountants
- Bankers to the Company – HDFC Bank
Inventia Healthcare Limited IPO Review by Top 10 Stock Brokers
|Top Stock Brokers Review||Company Reputation||Competitive Edge||Financial Statement||Popularity Index||Promoters Reputation|
Inventia Healthcare Limited IPO Grey Market Premium
The Inventia Healthcare Limited IPO Grey Market Premium price is Rs X, the Kostak rate is Rs X and the Subject to Sauda is X.
Open Free* Demat A/C Now! Fill the details below
Inventia Healthcare Limited IPO News
News 1 – IPO ISSUE OPENS SOON (Download Prospectus)